VTGN
VistaGen Therapeutics Inc
0.273$
-7.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 39.2% | 86.4% | 91.0% | 97.7% | 97.4% | 27.4% | 96.2% | 95.1% | 83.0% | 97.6% | 97.3% | 96.7% | |
| 26.0% | 43.3% | 78.7% | 92.0% | 93.5% | 23.5% | 95.2% | 91.3% | 78.9% | 96.4% | 79.6% | 63.4% | |
| 26.0% | 43.3% | 78.7% | 92.0% | 93.5% | 23.5% | 95.2% | 91.3% | 78.9% | 96.4% | 95.4% | 93.5% | |
| – | – | – | – | 2.1% | – | 0.0% | 3.7% | 3.8% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | 1.6% | – | 0.9% | 3.3% | -3.5% | – | – | – | |
| 43.4% | 8.9% | 7.7% | 1.8% | 2.2% | 65.6% | 3.3% | 0.6% | 13.1% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 7,716.9% | 400.8% | 83.4% | 38.7% | 49.5% | 199.3% | 15.1% | 13.3% | 42.7% | 7.6% | 16.5% | 26.9% | |
| 6,447.2% | 181.3% | 36.8% | 12.9% | 20.0% | 48.0% | 3.9% | 7.7% | 21.7% | 4.1% | 15.0% | 26.3% | |
| 5,165.2% | 4.5% | 1.5% | 0.5% | 0.4% | 6.5% | 0.3% | 0.6% | 2.8% | 0.4% | 0.7% | 1.6% | |
| 834.7% | 94.6% | 23.4% | 10.6% | 7.5% | 31.8% | 0.8% | 3.7% | 11.7% | 1.3% | 0.8% | 3.2% | |
| 123.0% | 2.7% | 0.3% | 0.1% | – | – | – | – | – | – | – | – | |
| -7,616.9% | -300.8% | 16.6% | 61.3% | 50.5% | -99.3% | 84.9% | 86.7% | 57.3% | 92.4% | 83.5% | 73.1% | |
| -31,339.5% | -13,310.1% | -3,825.2% | -1,388.0% | -1,292.7% | -3,497.9% | -203.0% | -358.5% | -1,549.9% | -288.1% | -483.3% | -982.9% | |
| 16.3% | 6.0% | 6.8% | 4.1% | 6.8% | 25.3% | 2.7% | 8.8% | 33.0% | 15.7% | 36.6% | 78.4% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.